{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:34:24Z","timestamp":1767854064292,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacc.2024.06.026","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:07:55Z","timestamp":1723025275000},"page":"1119-1122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?"],"prefix":"10.1016","volume":"84","author":[{"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.06.026_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jacc.2024.06.026_bib3","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ejhf.2660","article-title":"Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.026_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.jacc.2024.06.026_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure","volume":"109","author":"Ferreira","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacc.2024.06.026_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post-hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2024.06.026_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.026_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.026_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cardfail.2023.12.002","article-title":"Cardiovascular prevention in obese patients without diabetes: risk-based strategies are needed","volume":"30","author":"Ferreira","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2024.06.026_bib10","first-page":"767","article-title":"Semaglutide and cardiovascular outcomes","volume":"390","author":"Neves","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.026_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.026_bib12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2024.06.026_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ejhf.3184","article-title":"Dapagliflozin in patients with heart failure and previous myocardial infarction: a participant-level pooled analysis of DAPA-HF and DELIVER","volume":"26","author":"Peikert","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.026_bib14","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jacc.2020.03.074","article-title":"Recovery of left ventricular systolic function and clinical outcomes in young adults with myocardial infarction","volume":"75","author":"Wu","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.026_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.06.026_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect\u00a0of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2014 a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2024.06.026_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cardfail.2024.03.009","article-title":"Body mass index distribution among patients with heart failure and reduced ejection fraction: implication for future trials","volume":"30","author":"Butler","year":"2024","journal-title":"J\u00a0Card Fail"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972407774X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972407774X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T20:01:26Z","timestamp":1758139286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972407774X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S073510972407774X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.026","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}